Clorox Co-The

Clorox Q1 2026 earnings show modest EPS growth, flat revenue, and stable margins as the household‑care brand navigates inflation, supply‑chain pressures, and green‑cleaning trends.

Clorox’s flat Q4 earnings, amid a securities‑fraud probe, raise doubts about growth; analysts cut targets while the company explores sustainability and digital strategies.

Clorox beats Q3 earnings yet slashes 2026 sales outlook, sparking analyst downgrades and investor doubts. Discover how cost cuts, margin pressure, and regulatory scrutiny shape its future.

Clorox Q3 2026 results: flat net sales, modest margin pressure from costs, but EPS up thanks to cost cuts and the GOJO acquisition, while strengthening Purell and supply‑chain initiatives.

Clorox’s ex‑dividend date amid a 52‑week low: cash flow, regulatory risk, and green‑product opportunities shape investor decisions.

Clorox expands Hidden Valley Ranch with three new health‑friendly flavors, while accelerating digital supply‑chain upgrades to boost market share and shareholder value.

Clorox’s bleach‑based disinfectants stay top‑seller, but climate, VOC limits and green‑clean rivals challenge its 60% margin. Future success hinges on eco‑innovation, smart‑home links and Asia growth.

Clorox CFO’s April 1, 2026 sale of 244 shares—part of a Form 4 filing—reveals insider liquidity strategy, tax‑withholding impact, and hints at future growth plans or potential red flags.

Clorox’s director deferred‑compensation plan, tied to dividend‑reinvestment DSUs, boosts board equity by 0.06%—offering insight into governance, risks and strategic improvements.

Clorox insider buys: VP and chief of staff each purchase ~35,000 shares, nudging insider ownership to 2.4 %—small move, no price impact, but a sign of management aligning with shareholders.